Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,805 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dose Group 1 Clear all
Completed Phase 2 Interventional

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
NXN-462, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

NCT03434119
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
85
States / cities
Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone

NCT02617628
View directory record Official record
Conditions
Opiate Dependence
Interventions
extended release naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Alefacept in Kidney Transplant Recipients

NCT00543569
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Alefacept, tacrolimus, basiliximab, mycophenolate mofetil, Corticosteroids
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
38
States / cities
Loma Linda, California • Los Angeles, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Kuvan Therapy in Phenylketonuria (PKU): The Effect of Blood Phenylalanine Concentration on Kuvan Response

NCT00841100
View directory record Official record
Conditions
Phenylketonuria
Interventions
Kuvan, Diet
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
4 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide

NCT01458366
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Ofatumumab, Carboplatin, Etoposide, CT Scan, PET Scan, Stem Cell Transplant (STC)
Drug · Procedure · Genetic
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 23, 2026, 5:46 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

NCT06109272
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Livmoniplimab, Budigalimab, Durvalumab, Atezolizumab, Bevacizumab, Tremelimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
13
States / cities
Duarte, California • Irvine, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Feasibility of Minocycline in the Treatment of Traumatic Brain Injury (TBI)

NCT01058395
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Minocycline
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Dearborn, Michigan • Trenton, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Phase 2 Interventional Results available

Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma

NCT02394665
View directory record Official record
Conditions
Glioblastoma
Interventions
Intensity Modulated Radiation Therapy, Temozolomide, Functional Assessment of Cancer Therapy-Brain (FACT-Br), Stereotactic Radiosurgery Boost, Simultaneous Integrated Boost, 3D MRSI
Radiation · Drug · Behavioral + 1 more
Lead sponsor
University of Miami
Other
Eligibility
19 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Oct 23, 2026, 5:46 PM EDT
Active, not recruiting Phase 1 Interventional

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

NCT05743881
View directory record Official record
Conditions
Respiratory Syncytial Virus, Human Metapneumovirus
Interventions
mRNA-1345, mRNA-1365, Placebo, Nimenrix
Biological · Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
5 Months to 24 Months
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)

NCT02675400
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder (ADHD)
Interventions
Vyvanse, Behavioral Parent Training, Methylphenidate
Drug · Behavioral
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
21 Years to 55 Years · Male only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

A Phase I Study of ABT-510 in Combination With Bevacizumab in Advanced Solid Tumors

NCT00586092
View directory record Official record
Conditions
Solid Tumors
Interventions
bevacizumab, ABT-510
Drug
Lead sponsor
Herbert Hurwitz
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Not applicable Interventional

FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

NCT03291951
View directory record Official record
Conditions
Resistance Training, Colon Cancer, Chemotherapy Effect
Interventions
Resistance training
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Oakland, California • Boston, Massachusetts • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Phase 3 Interventional

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05882877
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
12 Years to 100 Years
Enrollment
2,621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
136
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 4 Interventional

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

NCT00087581
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Mycophenolate mofetil, Cyclosporine, Tacrolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
57
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 23, 2026, 5:46 PM EDT
Recruiting Not applicable Interventional

Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity

NCT07091500
View directory record Official record
Conditions
Obesity, Skeletal Muscle, Brain Connectivity
Interventions
Exercise training, Semaglutide, Therapy Cessation
Behavioral · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 23, 2026, 5:46 PM EDT
Terminated Phase 2Phase 3 Interventional

Mindfulness Training Plus Oxytocin Effects on Smoking Behavior

NCT03819231
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Oxytocin, Mindfulness, Saline Solution, Sham mindfulness
Drug · Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

NCT00206102
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine fumarate, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
63
States / cities
Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 1 Interventional

Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy

NCT03883919
View directory record Official record
Conditions
Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas
Interventions
5-FU, Leucovorin, Liposomal Irinotecan, Paricalcitol, Serum and plasma blood samples, Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis

NCT02471144
View directory record Official record
Conditions
Chronic Severe Plaque-type Psoriasis
Interventions
Experimental : Secukinumab low dose, Experimental: Secukinumab high dose, Placebo Comparator: Secukinumab Placebo, Active Comparator: Etanercept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria

NCT01169077
View directory record Official record
Conditions
Plasmodium Falciparum Malaria
Interventions
Placebo, EP-1300
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 16, 2012 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT04551677
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 84 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 23, 2026, 5:46 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

NCT02745392
View directory record Official record
Conditions
Acute Migraine
Interventions
ZP-Zolmitriptan, Placebo
Drug
Lead sponsor
Zosano Pharma Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Glendale, Arizona • Carlsbad, California • Huntington Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 23, 2026, 5:46 PM EDT